Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2007

View Archived Issues

A DYRK3 inhibitor shows potential for anemia therapy

New antidiabetic agents imparted in recent patents

Signs of activity seen with CPX-351 in leukemia, myelodysplastic syndrome

Phase II data on VNP-40101M in elderly AML patients reported

New therapeutics for cancer covered in recent patent literature

Recent Pharmacopeia patent reports novel antiparkinsonian agents

Wyeth Pharmaceuticals reports positive results from two phase III clinical studies of Pristiq

Oxford Biomedica initiates phase I/II trial of Prosavin for Parkinson's disease

FDA Cardio-Renal Advisory Committee requests further study of Solvay's tedisamil

FDA accepts ProEthic's NDA for PRO-513 for migraine headaches

GENimmune's HCV monoclonal antibody receives orphan medicinal product designation

FDA grants orphan drug status to Isis Pharmaceuticals' ISIS-333611 for ALS

ImClone initiates phase II clinical trial of IMC-1121B for metastatic malignant melanoma

Idera Pharmaceuticals initiates phase Ib trial of IMO-2055 for non-small cell lung cancer

Recordati acquires Orphan Europe

Novartis initiates phase II trial of QVA-149 for obstructive pulmonary disease

FDA advisory votes against approving Merck & Co.'s NDA for nonprescription Mevacor

Arena initiates BLOSSOM and BLOOM-DM phase III trials of lorcaserin for obesity

Phase II trial of ofatumumab in diffuse large B-cell lymphoma begins

MicroIslet holds pre-IND meeting with FDA regarding human clinical trial of MicroIslet-P

FDA accepts for review MGI Pharma's NDA for Aquavan

MediGene launches Veregen in the U.S. for genital and perianal warts

Chugai's Xeloda obtains Japanese approval for new indication in colon cancer

The CHMP of the EMEA recommends refusal of Neurochem's MAA for Kiacta

GSK receives FDA complete response letter regarding cervical cancer vaccine Cervarix

EMEA issues positive opinion recommending conditional approval of GSK's Tyverb

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...